Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CCEL's Cash to Debt is ranked higher than
93% of the 356 Companies
in the Global Medical Care industry.

( Industry Median: 0.20 vs. CCEL: No Debt )
CCEL' s 10-Year Cash to Debt Range
Min: 0.17   Max: No Debt
Current: No Debt

Equity to Asset -0.98
CCEL's Equity to Asset is ranked lower than
56% of the 341 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. CCEL: -0.98 )
CCEL' s 10-Year Equity to Asset Range
Min: -1.05   Max: 0.92
Current: -0.98

-1.05
0.92
Interest Coverage 1.72
CCEL's Interest Coverage is ranked higher than
51% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 5.80 vs. CCEL: 1.72 )
CCEL' s 10-Year Interest Coverage Range
Min: 1.22   Max: 9999.99
Current: 1.72

1.22
9999.99
F-Score: 8
Z-Score: -1.28
M-Score: -3.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.17
CCEL's Operating margin (%) is ranked higher than
76% of the 356 Companies
in the Global Medical Care industry.

( Industry Median: 8.32 vs. CCEL: 9.17 )
CCEL' s 10-Year Operating margin (%) Range
Min: -440   Max: 29.63
Current: 9.17

-440
29.63
Net-margin (%) 2.25
CCEL's Net-margin (%) is ranked higher than
66% of the 356 Companies
in the Global Medical Care industry.

( Industry Median: 4.54 vs. CCEL: 2.25 )
CCEL' s 10-Year Net-margin (%) Range
Min: -460   Max: 23.26
Current: 2.25

-460
23.26
ROA (%) 4.30
CCEL's ROA (%) is ranked higher than
74% of the 360 Companies
in the Global Medical Care industry.

( Industry Median: 3.60 vs. CCEL: 4.30 )
CCEL' s 10-Year ROA (%) Range
Min: -72.91   Max: 29.9
Current: 4.3

-72.91
29.9
ROC (Joel Greenblatt) (%) 176.53
CCEL's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 358 Companies
in the Global Medical Care industry.

( Industry Median: 16.45 vs. CCEL: 176.53 )
CCEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -340.07   Max: 183.43
Current: 176.53

-340.07
183.43
Revenue Growth (3Y)(%) 8.30
CCEL's Revenue Growth (3Y)(%) is ranked higher than
74% of the 278 Companies
in the Global Medical Care industry.

( Industry Median: 8.70 vs. CCEL: 8.30 )
CCEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -17.9   Max: 96.4
Current: 8.3

-17.9
96.4
EBITDA Growth (3Y)(%) 175.90
CCEL's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. CCEL: 175.90 )
CCEL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 175.9
Current: 175.9

0
175.9
» CCEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CCEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 63.50
CCEL's P/E(ttm) is ranked higher than
70% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 54.70 vs. CCEL: 63.50 )
CCEL' s 10-Year P/E(ttm) Range
Min: 3.88   Max: 520
Current: 63.5

3.88
520
PE(NRI) 63.50
CCEL's PE(NRI) is ranked higher than
71% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 51.80 vs. CCEL: 63.50 )
CCEL' s 10-Year PE(NRI) Range
Min: 3.91   Max: 114
Current: 63.5

3.91
114
P/S 1.33
CCEL's P/S is ranked higher than
74% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 1.99 vs. CCEL: 1.33 )
CCEL' s 10-Year P/S Range
Min: 0.28   Max: 5.1
Current: 1.33

0.28
5.1
PFCF 14.11
CCEL's PFCF is ranked higher than
90% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 148.91 vs. CCEL: 14.11 )
CCEL' s 10-Year PFCF Range
Min: 4.27   Max: 142
Current: 14.11

4.27
142
POCF 14.11
CCEL's POCF is ranked higher than
81% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 24.65 vs. CCEL: 14.11 )
CCEL' s 10-Year POCF Range
Min: 3.2   Max: 277
Current: 14.11

3.2
277
EV-to-EBIT 11.99
CCEL's EV-to-EBIT is ranked higher than
92% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 29.96 vs. CCEL: 11.99 )
CCEL' s 10-Year EV-to-EBIT Range
Min: -90.3   Max: 162.7
Current: 11.99

-90.3
162.7
Current Ratio 1.02
CCEL's Current Ratio is ranked higher than
63% of the 344 Companies
in the Global Medical Care industry.

( Industry Median: 1.36 vs. CCEL: 1.02 )
CCEL' s 10-Year Current Ratio Range
Min: 0.47   Max: 35.3
Current: 1.02

0.47
35.3
Quick Ratio 1.02
CCEL's Quick Ratio is ranked higher than
66% of the 344 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. CCEL: 1.02 )
CCEL' s 10-Year Quick Ratio Range
Min: 0.47   Max: 35.3
Current: 1.02

0.47
35.3
Days Sales Outstanding 78.02
CCEL's Days Sales Outstanding is ranked higher than
63% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 56.64 vs. CCEL: 78.02 )
CCEL' s 10-Year Days Sales Outstanding Range
Min: 13.89   Max: 128.82
Current: 78.02

13.89
128.82

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.97
CCEL's Price/Median PS Value is ranked higher than
89% of the 410 Companies
in the Global Medical Care industry.

( Industry Median: 1.40 vs. CCEL: 0.97 )
CCEL' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 84.38
Current: 0.97

0.29
84.38
Earnings Yield (Greenblatt) 8.30
CCEL's Earnings Yield (Greenblatt) is ranked higher than
91% of the 352 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. CCEL: 8.30 )
CCEL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 211.1
Current: 8.3

0.6
211.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Cryo-Cell International, Inc. was incorporated on September 11, 1989 in the State of Delaware. The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord9(r)) blood stem cells for family use. The Company has established private family cord blood stem cell banks in terms of the number of specimens preserved. Its headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations, including the processing and storage of specimens. The specimens are stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Oldsmar, Florida. It has expanded its research and development activities to develop technologies related to stem cells other than umbilical cord blood stem cells. During 2006, in parallel with its R&D associated with placental stem cells, the Company discovered novel technology related to menstrual stem cells. In November 2007, the Company announced the launch of its C'elleSM service related to this patent-pending technology, and the Company continues to focus its current research and development activities mainly on the C'elle service and related new menstrual stem cell technologies. The Company is actively marketing the C'elle service both through a bundled offer with the Company's U-Cord service and on a stand-alone basis. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, Lamaze instructors and other childbirth educators, certified nurse-midwives and other related healthcare professionals. To increase awareness among expectant parent audiences, the Company continues to promote its service in several national targeted prenatal magazines including American Baby and Fit Pregnancy, as well as several magazines distributed during childbirth classes. Expectant parents have also received information via emails and the Company has increased its internet marketing campaigns. Its competitors are Cord Blood Registry, Inc., ViaCord, a division of ViaCell, Inc., a wholly-owned subsidiary of PerkinElmer and LifeBankUSA, a division of Celgene. The Company is required to register with the FDA under the Public Health Service Act.
» More Articles for OTCPK:CCEL

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
10-Q for Cryo-Cell International, Inc. Apr 23 2015
CRYO CELL INTERNATIONAL INC Financials Apr 18 2015
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 15 2015
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2015 Financial Results Apr 15 2015
CRYO CELL INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Apr 14 2015
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 13 2015
Cryo-Cell International files suit, suggests takeover of rival firm Apr 03 2015
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 02 2015
Cryo-Cell International, Inc., Cord Blood Banking Leader, Takes Significant Ownership Stake in Cord... Mar 31 2015
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 10 2015
10-K for Cryo-Cell International, Inc. Mar 04 2015
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 04 2015
CRYO CELL INTERNATIONAL INC Files SEC form 10-K/A, Annual Report Mar 04 2015
Cryo-Cell Reports Financial Results for Fiscal 2014 Mar 03 2015
CRYO CELL INTERNATIONAL INC Files SEC form 10-K, Annual Report Mar 02 2015
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Dec 03 2014
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 16 2014
CRYO CELL INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Oct 15 2014
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Sep 26 2014
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK